DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $132,187,680 | +51.0% | 532,800 | +46.1% | 0.30% | +54.5% |
| Q2 2023 | $87,552,000 | -3.5% | 364,800 | +1.3% | 0.19% | +2.7% |
| Q1 2023 | $90,734,400 | +25.9% | 360,000 | +32.6% | 0.19% | +66.1% |
| Q4 2022 | $72,061,530 | +248.7% | 271,500 | +239.3% | 0.11% | +250.0% |
| Q3 2022 | $20,666,000 | +64.1% | 80,006 | +61.0% | 0.03% | +166.7% |
| Q2 2022 | $12,595,000 | -9.4% | 49,688 | +4.8% | 0.01% | +50.0% |
| Q1 2022 | $13,907,000 | -81.8% | 47,410 | -79.5% | 0.01% | -88.4% |
| Q4 2021 | $76,266,000 | -36.2% | 231,800 | -40.9% | 0.07% | -23.3% |
| Q3 2021 | $119,490,000 | +1265.8% | 392,500 | +1104.2% | 0.09% | +1025.0% |
| Q2 2021 | $8,749,000 | +176.7% | 32,595 | +132.4% | 0.01% | +166.7% |
| Q1 2021 | $3,162,000 | -96.7% | 14,026 | -96.8% | 0.00% | -95.8% |
| Q4 2020 | $96,112,000 | -56.5% | 432,686 | -57.9% | 0.07% | -56.7% |
| Q3 2020 | $221,154,000 | +105.6% | 1,027,034 | +68.8% | 0.16% | +30.2% |
| Q2 2020 | $107,575,000 | +425.8% | 608,377 | +311.6% | 0.13% | +384.6% |
| Q1 2020 | $20,458,000 | +355.5% | 147,801 | +405.1% | 0.03% | +420.0% |
| Q4 2019 | $4,491,000 | +457.2% | 29,262 | +424.0% | 0.01% | +400.0% |
| Q3 2019 | $806,000 | +291.3% | 5,584 | +287.2% | 0.00% | – |
| Q2 2019 | $206,000 | +17.0% | 1,442 | +8.2% | 0.00% | – |
| Q1 2019 | $176,000 | +8.6% | 1,333 | -15.6% | 0.00% | – |
| Q4 2018 | $162,000 | +118.9% | 1,579 | +133.9% | 0.00% | – |
| Q3 2018 | $74,000 | -98.8% | 675 | -98.9% | 0.00% | -100.0% |
| Q2 2018 | $6,168,000 | +17522.9% | 62,500 | +17213.0% | 0.01% | – |
| Q1 2018 | $35,000 | -99.9% | 361 | -99.9% | 0.00% | -100.0% |
| Q4 2017 | $53,076,000 | +54.7% | 571,820 | +43.0% | 0.07% | +30.4% |
| Q3 2017 | $34,312,000 | +35.5% | 400,000 | +33.3% | 0.06% | +14.3% |
| Q2 2017 | $25,317,000 | -3.6% | 300,000 | -2.2% | 0.05% | -9.3% |
| Q1 2017 | $26,249,000 | -66.9% | 306,900 | -69.9% | 0.05% | -65.2% |
| Q4 2016 | $79,250,000 | -15.8% | 1,018,100 | -15.2% | 0.16% | -11.4% |
| Q3 2016 | $94,093,000 | -8.6% | 1,200,300 | +17.8% | 0.18% | -14.2% |
| Q2 2016 | $102,950,000 | +153.8% | 1,019,300 | +138.4% | 0.20% | +126.7% |
| Q1 2016 | $40,566,000 | +3.1% | 427,622 | +0.9% | 0.09% | +12.5% |
| Q4 2015 | $39,363,000 | +411.9% | 423,810 | +369.6% | 0.08% | +370.6% |
| Q3 2015 | $7,690,000 | -96.1% | 90,247 | -96.1% | 0.02% | -95.9% |
| Q2 2015 | $198,269,000 | +143.2% | 2,316,500 | +141.2% | 0.42% | +116.6% |
| Q1 2015 | $81,525,000 | +20.8% | 960,237 | +22.0% | 0.19% | -1.5% |
| Q4 2014 | $67,482,000 | +10.2% | 787,308 | -2.3% | 0.20% | +1.0% |
| Q3 2014 | $61,246,000 | +23.0% | 806,076 | +27.4% | 0.19% | -5.4% |
| Q2 2014 | $49,810,000 | +566.8% | 632,661 | +535.5% | 0.20% | +365.9% |
| Q1 2014 | $7,470,000 | +1582.4% | 99,557 | +1631.4% | 0.04% | +2100.0% |
| Q4 2013 | $444,000 | -14.9% | 5,750 | -23.4% | 0.00% | -50.0% |
| Q3 2013 | $522,000 | +755.7% | 7,510 | +667.1% | 0.00% | – |
| Q2 2013 | $61,000 | – | 979 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |